Gregg Klofenstine

The healthcare industry is currently grappling with a significant challenge - its reactionary approach to hiring and recruiting. Many leaders find themselves in a reactive position, leaving little room for consultation and resulting in ineffective processes and ideologies. It's crucial to consult with experts well ahead of any perceived needs, be it timing, accuracy, or market positioning. At our service, we are here to provide the guidance you need to navigate towards your desired destination. #posthiresupport #advancedprovidersupport 

2

3 Comments

Port City Labs has already made a splash. We recently completed our first retained search project in record breaking speed. Lead Recruiter: Shawn Friend Project: Director, Clinical Development Client: Pre-IPO oncology biotech under 100 employees Requirements: Oncologist with targeted experience in neurology 🔆 Number of candidates presented: 5 🔆 Days to complete: 45 🔆 Number of offers extended: 1 🔆 Hired candidate presented: Day 6 Elite talent needs to be targeted. Our group has been partnering with pharmaceutical and venture-backed biotech organizations for 20+ years. We excel in finding your "special" needle in a stack of needles. It would be an honor to hear your story and march towards a collaborative solution in Clinical Development, Clinical Operations, Biometrics, Program Management, C-Suite, and Board opportunities. Port City Labs - Our "Why" is "You". #biotech #lifesciences #oncology #neurology #portcitylabs

17

1 Comment

📈 Exact Sciences Stock Surges on Higher Medicare Pricing for Cologuard Plus! 💡 Big news in the world of diagnostics! Exact Sciences' next-gen Cologuard Plus test has been priced at $592 by CMS—16% higher than the original Cologuard test ($508). This unexpected decision has sent Exact Sciences' stock soaring, rising by as much as 11% on Tuesday. Here's why it matters: ✅ FDA-Approved Innovation: Cologuard Plus, approved just last month, uses advanced methylation testing on three genes (LASS4, LRRC4, PPP2R5C) to detect colorectal cancer. ✅ Higher Reimbursement Rate: After CMS initially proposed pricing it the same as the original Cologuard, the final rate reflects a more nuanced framework combining three Septin 9 tests ($192 each) and a FIT test ($15). ✅ Launch Timeline: The test is set to go live commercially in Q1 or Q2 2025, with new CMS pricing effective Jan. 1, 2025. 💡 Why the Buzz? This pricing clarity reduces investor uncertainty and sets the stage for a potential 10% price increase from commercial payors, according to Evercore ISI analyst Vijay Kumar. With Medicare fee-for-service patients representing 15-20% of the Cologuard population, this is a major win for Exact Sciences! As diagnostics evolve, better tools for early cancer detection like Cologuard Plus can lead to healthier futures. This news isn’t just about pricing—it’s about progress. 💬 What do you think of the role of innovative pricing frameworks in supporting better healthcare solutions? #HealthcareInnovation #Diagnostics #ExactSciences #CologuardPlus #CancerScreening #Medicare #StockMarket

1

1 Comment

Any #Medtech leaders looking to scale their commercial operation, then you should probably know this man Mike Kosikas and his company Bridgeview Leadership Group   Mike's had an incredible commercial career, most recently at LivaNova spanning 11 years with half-a-dozen promotions; followed by another successful tenure at Abbott.   Now, Mike is uses his experience to help other #NeuroTech and MedTech companies scale their commercial operations via his own business.   Mike’s experience across five different #neuromodulation businesses in a variety of sales, sales leadership and functional leadership roles means he can wear almost any hat in the commercial organization while leveraging cross-functional expertise.  If you have any issues or needs around #salestraining, #executivecoaching, #leadershipdevelopment or commercial #processdevelopment, then Mike could be the man for you to wheel in.   Definitely worth following too as he posts loads of valuable content on those topics. Great catch-up yesterday Mike 👍

28

9 Comments

CDMO Nucleus RadioPharma reveals expansions at two sites that will "significantly improve" market access to promising cancer treatments. 🏗️ The upgrades at sites in Mesa, #Arizona and Springhouse, #Pennsylvania will give each facility research, development and commercial production capabilities, boosting capacity by 200%. The expansions are expected to be completed by the end of 2026 and will create around 100 jobs overall. 💉 The upgrades will allow more patients to receive radiopharmaceuticals, which have a limited shelf-life, according to Nucleus. 💬 "To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them," Nucleus RadioPharma CEO Charles Conroy, RPh, MBA said in a release. "Our expansion will significantly improve patient access to these life-saving treatments and expedite clinical trials, potentially reducing time-to-market for new therapies by up to 30%." #CDMO #Radiopharmaceuticals #Radiopharma

13

Caris Life Sciences 𝗮𝗻𝗱 COTA 𝗧𝗲𝗮𝗺 𝗨𝗽 𝘁𝗼 𝗔𝗱𝘃𝗮𝗻𝗰𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗗𝗮𝘁𝗮. 𝗟𝗲𝗮𝗱𝗶𝗻𝗴 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗖𝗮𝗿𝗶𝘀 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝗻𝗱 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗱𝗮𝘁𝗮 𝗲𝘅𝗽𝗲𝗿𝘁 𝗖𝗢𝗧𝗔, 𝗜𝗻𝗰. 𝗮𝗿𝗲 𝗷𝗼𝗶𝗻𝗶𝗻𝗴 𝗳𝗼𝗿𝗰𝗲𝘀 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁. This collaboration will combine Caris' massive dataset of genetic, imaging, and other molecular data with COTA's real-world data on patient treatments and outcomes. This rich resource will be a boon for researchers, giving them new insights to develop more effective and personalized cancer therapies. 𝙃𝙚𝙧𝙚'𝙨 𝙬𝙝𝙖𝙩 𝙩𝙝𝙞𝙨 𝙢𝙚𝙖𝙣𝙨 𝙛𝙤𝙧 𝙘𝙖𝙣𝙘𝙚𝙧 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝: • 𝘔𝘰𝘳𝘦 𝘱𝘰𝘸𝘦𝘳𝘧𝘶𝘭 𝘥𝘢𝘵𝘢 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮 - By combining their strengths, Caris and COTA are creating a unique platform for researchers. This platform will offer a comprehensive view of cancer at the molecular level and how it responds to treatments in real-world settings. • 𝘍𝘢𝘴𝘵𝘦𝘳 𝘥𝘳𝘶𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 - With a clearer understanding of cancer and patient responses, researchers can design better clinical trials and accelerate the development of new drugs. • 𝘐𝘮𝘱𝘳𝘰𝘷𝘦𝘥 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 - Ultimately, this collaboration aims to deliver more effective personalized treatments to patients, improving their prognosis and quality of life. #cancerresearch #precisionmedicine #realworlddata #oncology #drugdiscovery 

5

🔍 Today's Focus: Dermatology Prior Authorization Process ✨ Understanding the Importance of Prior Authorization in Dermatology Prior authorizations play a crucial role in ensuring that patients receive timely and appropriate care. 🏥 Case Study: A patient with psoriasis requires a specific biologic medication for treatment. Without prior authorization, delays in approval can hinder the patient's access to this necessary medication, impacting their quality of life. 🩺 Key Points to Note for Dermatology Prior Authorizations: 1. Dermatological procedures such as skin biopsies, laser therapy, and chemical peels often require prior authorization due to their specialized nature. 2. Insurance companies may have specific criteria that need to be met before approving certain dermatological treatments, highlighting the importance of accurate documentation. 3. Collaborating closely with dermatologists and insurance providers is essential to streamline the prior authorization process and ensure efficient approvals. 🌟 Do you have any experience with dermatology prior authorizations? Share your insights below! 🔗 #Dermatology #PriorAuthorization #SkinHealth 🌟 If you are looking for Prior Authorization Outsourcing Services, please connect with me via email at [email protected] or by scheduling a Meeting at https://lnkd.in/e4nbe7jV

3

The specialty pharmacy landscape is evolving faster than ever! With advancements like gene therapies, biosimilars, and rare disease treatments, specialty pharmacies are redefining how patients receive complex medications. At MedOp Solutions, we’re not just keeping up—we’re leading the charge.💪 Our dedicated focus on specialty services allows us to provide highly tailored, patient-centric solutions that align with value-based care and innovative cost-management strategies. We're committed to being a reliable partner in this rapidly changing sector, supporting our clients and patients with solutions that enhance quality care and accessibility. 🌐💊 Check out the latest trends shaping specialty pharmacy and our role in this transformative journey! 📖 Read more about these key trends here: AscellaHealth's 2024 report Business Wire s://https://lnkd.in/gnb3Xvzu). #medopsolutions #pharmacy #nowhiring

8

Want to learn more about who has the best pay in Life Sciences?  Read our blog, "Who Has the Best Pay in Life Sciences? A Study," by SRG SVP of Delivery & Strategy, Patrick H. Stedman, and see how careers have evolved over the years and why the job market is more attractive than ever. Learn about the views of over 4,000 #STEM industry professions on hybrid working, AI, diversity, culture, and what candidates want in an employer.  Our SRG Talent Trends & Insights report was done in partnership with New Scientist Jobs, which has been tracking the salaries of professional scientists for more than 20 years. The goal was to quantify earnings and how they are changing and study the differences by geography, demographics, and skills. Read more below:  https://lnkd.in/euDnRxPa

15

Industry Weekly Update 💊 - MaaT posts 18-month data showing 'clear OS advantage' in aGvHD. - Roche picks up Prenosis' sepsis AI tool for distribution. - Portage Biotech hints at potential closure as it halts programs. - Steris carves out dentistry equipment business for $787M. - Poseida examines CAR-T conditioning to crack into solid tumours. - Illumina gets go-ahead from EU to part ways with Grail. - US court hands Philips final consent decree in CPAP recall. - MoonLake and Komodo sign deal for health analytics tech. - J&J funds Rallybio in risk-busting rare pregnancy disease pact.

4

Another day, another reason why you should join us at IQVIA, seriously what are you waiting for??? As a #ClinicalResearchAssociate you will have access to top-tier training resources, encompassing everything from virtual learning modules to hands-on activities and comprehensive mentorship programs. These tools will not only enhance your professional skills but also empower you to make significant contributions to the field of clinical research. Curious about the limitless possibilities of our #CRA Training Program? Find out more here: https://bit.ly/3RzHUWf #IQVIA #ClinicalResearch #ProfessionalDevelopment"

9

🔍 April 2024 Update: Clinical Data Management (CDM) Job Market Insights Here's a detailed snapshot of the CDM job market as of April 2024, highlighting key trends, employer data, and the attributes most valued by professionals in the field: 1. Total Professionals: The industry hosts 6,325 professionals specializing in CDM. 2. Job Mobility: Notably, there were 774 job changes within the past year. 3. New Job Posts: There are 146 new job postings for clinical data managers. 4. Market Misalignment: Over 31% of CDM job postings remained unfilled for more than 3 months—a critical gap in talent acquisition. 5. Engagement Levels: Currently, 716 talents are highly engaged within the CDM sector. 6. Top Employers: Leading companies like PPD, Pfizer, and Bristol Myers Squibb have significant employment numbers but vary in attrition rates:   - PPD: 4% attrition rate   - Pfizer: 6% attrition rate   - Bristol Myers Squibb: 13% attrition rate 7. Rising Stars:   - Merck: Positive growth of 16% and a low attrition rate of 3%.   - Amgen: 13% increase in CDM professionals with a minimal attrition rate of 1%. 8. Challenges:   - Emmes: Experienced a 31% reduction in professional count and a high attrition rate of 36%. 9. Skill Demand: Fastest-growing skills include CRO Oversight and Artificial Intelligence, with increases of 288% and 253%, respectively. 10. Value Propositions: When considering job offers, the most important factors for clinical data management (CDM) professionals are compensation (91%), work-life balance (78%), and opportunities for career advancement (71%). 11. Least Valued Factors: Diversity, equity, and inclusion (DEI) initiatives were valued by only 10% of CDM professionals when evaluating potential jobs. Just 13% highly valued working for a company driven by values aligning with their own, and only 16% placed strong importance on a collaborative company culture. 12. Industry Hiring Trends:    - Pharmaceutical: Steady employment growth of 7%.    - Biotechnology: Slight decline of 2%. - Clinical Research Organization: Decrease of 6% 13. Gender Dynamics: 67% of the CDM workforce is female. 14. Median Tenure: CDM professionals typically stay with an organization for an average of 2.3 years. 15. Salary Insights: Firms that pay salaries in the highest 25% for similar positions tend to keep their CDMs 3x longer than those paying in the lowest 25%. These insights not only reflect the current state of the CDM job market but also serve as a strategic guide for professionals and companies to effectively manage their career paths and talent acquisition strategies. Stay tuned for more updates and tailor your career strategies accordingly! 🚀 #PharmaCareers #BiotechJobs #ClinicalDataManagement #TalentTrends #IndustryInsights

44

Adapting to Thrive: Overcoming Challenges in Med-Tech Leadership Leaders in med-tech, you face unique challenges. -The rapid pace of technology. -Navigating complex regulations. -Finding and retaining top talent. But these challenges also present opportunities. -Embrace continuous learning. -Innovate and adapt quickly. -Build a dynamic and skilled team. Your efforts will drive the next wave of medical technology innovations. Stay focused, stay determined, and lead with vision. What's your strategy for keeping up with tech advancements?

3

The final chapter of 2024 is here —a month filled with holiday cheer, reflection, and planning for what’s next. It's a time to celebrate the wins of this year and gear up for the exciting opportunities 2025 has in store. For those of us in the staffing and recruiting world, 2025 is looking promising. With anticipated industry growth after two challenging years, there’s a lot to look forward to. But there’s no need to wait for January to get started! The groundwork we lay this month will be the launchpad for success in the new year. As we embrace the holiday spirit and take stock of 2024, here’s a few things to think about: - Opportunities for growth: Are your tech stack and processes ready to capitalize on the rebound? - Holiday gratitude: Taking time to appreciate clients, partners, and colleagues who make it all happen. - Future-focused strategy: Ending the year strong by setting the stage for an impactful Q1 2025. Are you reflecting on 2024, finalizing plans for next year, or just soaking up the holiday season? Here’s to making December count and welcoming 2025! #PARQA #staffingandrecruiting #Salesforce #Bullhorn #optimization

11

1 Comment

Our latest blog dives into the importance of cell density, even distribution and the science behind effective seeding techniques. Learn how understanding these steps can lead to more precise evaluations of cellular reactivity. https://lnkd.in/gYhukzVr blog&utm_term=&utm_marketing_tactic=aw #CellCulture #Cytotoxicity #CellSeeding

3

🚨 10 Key Takeaways from "Behind Big Pharma's layoffs — is there an end in sight?" 🚨 1️⃣ Massive Job Losses: In 2023, the biopharma industry saw around 14,000 job losses due to layoffs. 2️⃣ Bristol Myers Squibb Cuts: The company plans to eliminate 2,200 jobs by 2025, including 860 in New Jersey. 3️⃣ Bayer Restructuring: Bayer has already reduced its workforce by 1,500, with more layoffs possible. 4️⃣ Expense Trends: Pharma companies' selling, general, and administrative expenses have stayed at 29% for decades, while R&D spending has risen from 12% to nearly 18% of revenue since 2000. 5️⃣ Funding Worries: An EY Biotech report reveals that 31% of biotechs may run out of funds within a year. 6️⃣ High-Demand Skills: Digital technology, AI, and market access skills are currently in high demand. 7️⃣ AI's Impact: An EY-Parthenon report suggests AI could drive future hiring in biopharma as it becomes crucial in drug development. 8️⃣ Economic Shifts: The European Central Bank has cut interest rates from a high of 4% as inflation decreases, while the Federal Reserve has yet to follow suit. 9️⃣ Political Uncertainty: The November 2024 election is unpredictable and could impact the industry, though effects will only be known post-election. 🔟 Future Outlook: Arda Ural of EY predicts a potential return to normalcy by 2025, with the worst of the layoffs possibly over by then. Stay tuned for more insights and trends from the biopharma industry! 💡✨ #Pharma #Biotech #Layoffs #JobMarket #AI #Innovation #Healthcare #Economy #FutureTrends

3